AGEN - Agenus Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.67
-0.03 (-1.76%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.70
Open1.70
Bid1.67 x 4000
Ask1.74 x 28000
Day's Range1.57 - 1.72
52 Week Range1.57 - 6.19
Volume1,403,168
Avg. Volume1,403,063
Market Cap173.678M
Beta2.80
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire4 days ago

    Agenus Receives Second Milestone Payment from Merck

    LEXINGTON, Mass., Aug. 15, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Merck, known as MSD outside the United States and Canada, initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration. Based on this milestone and under the terms of the agreement, Agenus received a $4 million milestone payment and is entitled to receive up to an additional $95 million in success milestones from Merck. "We continue to deliver on all milestones with our existing partners." said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.

  • PR Newswire10 days ago

    Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    - Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, Mass. , Aug. ...

  • ACCESSWIRE10 days ago

    Agenus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. To listen ...

  • PR Newswire17 days ago

    Agenus to Report Second Quarter 2018 Financial Results on August 9, 2018 and Host Conference Call and Webcast

    LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , ...

  • GlobeNewswire23 days ago

    New Research: Key Drivers of Growth for Cadence Design, Agenus, Foundation Medicine, Honeywell International, NeoPhotonics, and Citrix — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cadence ...

  • PR Newswirelast month

    Agenus Appoints Regulatory and Clinical Heads

    LEXINGTON, Mass., July 16, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies1, today announced the appointment of I-O drug development experts into key leadership positions.  These appointments will help advance multiple clinical programs and planned BLA filings by 2020. Drs. Gupta and Wijatyk have had successful careers leading the approvals of immune therapies and chemotherapies," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. Dr. Sunil Gupta joins Agenus as Vice President of Regulatory and Pharmacovigilance.  Dr. Gupta is a trained oncologist with nearly 30 years in senior leadership positions in clinical development and regulatory affairs.

  • PR Newswire2 months ago

    Agenus to Webcast Annual Meeting of Stockholders

    LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 invites ...

  • CNW Group2 months ago

    National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up

    National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up

  • PR Newswire2 months ago

    Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell

    LEXINGTON, Mass., June 12, 2018 /PRNewswire/ -- A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4.  Agenus has applied this discovery to its proprietary next generation anti-CTLA-4 antibody (AGEN1181) on track for IND filing in 2H2018. The pre-clinical study reports on a unique mechanism discovered by Agenus, that can significantly improve the biological and immunological activity of certain cancer fighting antibodies, such as those targeting CTLA-4 and TIGIT.

  • ACCESSWIRE2 months ago

    Today’s Free Research Reports Coverage on Agenus and Three More Biotech Stocks

    In today's pre-market research, WallStEquities.com evaluates Affimed N.V. (NASDAQ: AFMD), Agenus Inc. (NASDAQ: AGEN), Akcea Therapeutics Inc. (AKCA), and Akebia Therapeutics Inc. (NASDAQ: AKBA). The Company's shares are trading 8.38% above their 200-day moving average.

  • PR Newswire2 months ago

    Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY

    Presentation Time and Location: Thursday, Jun 7 at 4:30-4:55 PM EDT in Ballroom to be followed by a breakout session at 5:00-05:25 PM EDT in Uris. A live audio webcast will be accessible on the "Events & Presentations" section of the Company's investor website at www.agenusbio.com where a replay will also be available following the presentation.

  • PR Newswire2 months ago

    Agenus Presents Clinical Responses of AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-PD-1) at ASCO 2018

    - AGEN1884 and AGEN2034 produce clinical benefit2 in 31% and 42% of patients respectively - Combination trial of AGEN1884 plus AGEN2034 in 2L cervical cancer ongoing to support BLA LEXINGTON, Mass. , June ...

  • PR Newswire3 months ago

    Agenus to Present Clinical Data on Lead Programs at ASCO 2018

    - AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses - More than 100 patients treated with AGEN1884 and AGEN2034 - Combination trial has commenced in cervical cancer LEXINGTON, Mass. ...

  • PR Newswire3 months ago

    Agenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston

    LEXINGTON, Mass. , May 7 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , ...

  • PR Newswire3 months ago

    Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update

    Agenus to host conference call and webcast today at 11am ET LEXINGTON, Mass. , May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint ...

  • ACCESSWIRE3 months ago

    Agenus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 11:00 AM Eastern Time. To listen to ...

  • PR Newswire4 months ago

    Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast

    LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will ...

  • AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA
    PR Newswire4 months ago

    AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA

    LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments ...

  • PR Newswire4 months ago

    Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting

    LEXINGTON, Mass. , April 11 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that three ...

  • PR Newswire5 months ago

    Agenus to Present at Healthcare Investor Conferences In April

    LEXINGTON, Mass., March 29, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's leadership will present and host one-on-one meetings at two healthcare investment conferences in April. Jennifer Buell, Ph.D., Chief External Affairs and Communications Officer of Agenus, will present on Agenus and AgenTus at the Jefferies IO Cell Therapy Summit on April 3, 2018, at the Boston Harbor Hotel, Boston, Massachusetts. Corporate presentation is at 7:55 a.m. ET.

  • PR Newswire5 months ago

    Agenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

    LEXINGTON, Mass. , March 15, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update ...

  • ACCESSWIRE5 months ago

    Agenus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018 at 11:00 AM Eastern Time. To listen ...

  • PR Newswire5 months ago

    Agenus to Report Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 and Host Conference Call and Webcast

    LEXINGTON, Mass. , March 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter ...

  • PR Newswire7 months ago

    Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)

    LEXINGTON, Mass., Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies. This Phase 1/2 clinical trial launched in December 2017 and enrollment into the first cohort has been rapidly completed. The optimal combination dose and schedule will be evaluated in an expansion cohort of patients with inoperable cervical cancer who have relapsed after platinum-containing chemotherapy. In addition, we believe both agents are crucial for combinations with our portfolio of proprietary immune oncology therapeutics," said Garo Armen, Ph.D., Chairman and CEO of Agenus.